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We investigated the effect of expression of constitu-
tively active Ga mutants on cell survival. Transfection
of constitutively active Gaq and Ga13 in two different
cell lines caused condensation of genomic DNA and nu-
clear fragmentation. Endonuclease cleavage of genomic
DNA was followed by labeling the DNA fragments and
subsequent flow cytometric analysis. The observed cel-
lular phenotype was identical to the phenotype dis-
played by cells undergoing apoptosis. To distinguish be-
tween the apoptosis-inducing ability of the two Ga-
subunits, the signaling pathways involved in this
cellular function were investigated. Whereas Gaq in-
duced apoptosis via a protein kinaseC-dependent path-
way, Ga13 caused programmed cell death through a
pathway involving the activation of the small G-protein
Rho. Both of the pathways leading to apoptosis were
blocked by overexpression of bcl-2. In contrast to other
apoptosis-inducing systems, expression of constitu-
tively active Gaq and Ga13 triggered apoptosis in high
serum as well as in defined medium.
There are two distinct modes of death in cellular systems. In
one, an insult leading to irreversible cellular injury causes a
phenotype called necrosis that is manifested by the rupture of
the cell membrane. In the other, under certain physiological
situations, death of cells is triggered by metabolic or develop-
mentally programmed events and may be required for the
organisms survival or for differentiation (1). This programmed
cell death (apoptosis) occurs when a cell dies by a mechanism
initiated by proteins encoded by its own genome.
Apoptosis can be distinguished from necrosis through mor-
phological characteristics including cell shrinkage, chromatin
condensation, activation of specific proteases and endonucle-
ases, and fragmentation of genomic DNA (2). Apoptosis has
been implicated in many important biological processes includ-
ing immune defense, growth control, and development (3).
In addition some events leading to human disease involve
apoptosis (4, 5).
The execution of apoptosis is triggered by intrinsic signal
transduction events that link changes in physiological condi-
tions to the cell death machinery. Signal transduction through
seven pass membrane receptors represents a common mecha-
nism of eukaryotic signaling and physiological control. During
this process heterotrimeric G-proteins are responsible for
transducing a ligand binding event at the membrane into a
cellular response (6, 7). There are four different classes of
Ga-subunits that contribute to heterotrimeric G-proteins me-
diated responses (8). In addition to tight regulation of activa-
tion of signal transduction pathways the cell also contains a
carefully regulated system to shut down signaling after pro-
longed exposure to ligands. This desensitization is primarily
achieved by phosphorylation induced inactivation of the recep-
tor and subsequent internalization of the phoshorylated recep-
tor (9). Recently a desensitization mechanism directly acting at
the a-subunits was discovered. GAP proteins were cloned that
accelerate the intrinsic GTPase activity of a-subunits thereby
shutting off the signal (10).
In some situations permanently elevated levels of second
messengers are observed inside the cells. It is believed that
these elevated activities contribute to the execution of patho-
logical phenotypes (11). Recent data point to the involvement of
the Ga-subunit, Gao, in the execution of apoptosis triggered by
a mutated and presumably constitutively active amyloid pre-
cursor protein (APP) in Alzheimer’s disease (12).
To investigate the effect of other constitutively active G-
protein subunits, we examined their ability to cause apoptosis
in vivo. Constitutively active mutants of Gaq, Ga12, Ga13, and
Gai2 were expressed in CHO1 and COS-7 cells, and the result-
ing cellular phenotypes were observed.
EXPERIMENTAL PROCEDURES
Materials—The dye Hoechst 33258 was obtained from Sigma. The
Texas red conjugated goat antibodies to rabbit immunoglobulin G (IgG)
and the polyclonal antibodies to b-galactosidase were received from
Cappel and 5 Prime3 3 Prime, Inc., Boulder, CO, respectively. Profec-
tin Ca3(PO4)2 Transfection kit was purchased from Promega. Protein
kinase C inhibitors and EGTA/AM were received from Calbiochem. Cell
culture and transfection reagents including DMEM, FBS, serum free
medium (Optimem), LipofectAMINE, and trypsin/EDTA were pur-
chased from Life Technologies, Inc., whereas Ham’s F-12 was received
from Irvine Scientific. The Apo-Direct kit was obtained from Phoenix
Flow Systems. The peptide inhibitor, benzyloxycarbonyl-Val-Ala-Asp-
fluoromethylketone (z-VAD.fmk), was purchased from Enzyme Systems
Products. The in situ cell death detection kit was obtained from Boeh-
ringer Mannheim, and the Vectashield mounting medium containing
49,6-diamidino-2-phenylindole was from Vector Laboratories.
Cell Culture and Maintenance—Cells were grown in 5% CO2 and
DMEM, 10% FBS (COS-7), or Ham’s F-12, 10% FBS (CHO-K1), respec-
tively. Transfection protocols for COS-7 and CHO-K1 cells with Lipo-
fectAMINE were described previously (13). Cells were kept in serum-
free medium during LipofectAMINE transfection for 5 h and followed
by the addition of an equal volume of DMEM, 20% FBS. Transfection of
COS-7 cells with the Perfectin kit was performed according to the
manufacturer’s instructions in DMEM, 10% FBS. Treatment of COS-7
cells with z-VAD.fmk was performed according to the peptide manufac-
turer’s directions. Immediately after transfection of cells using lipo-* This work was supported by National Institutes of Health Grant
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fectAMINE, z-VAD.fmk was added to a final concentration of 50 mM.
Cells were maintained in medium containing 50 mM z-VAD.fmk for
approximately 41 h. New aliquots of the peptide inhibitor were added 4
times during the course of the incubation period to ensure that the
effectiveness of the inhibitor was maximized.
Expression Plasmids—Expression plasmids for Ga13QL, GaqRC,
LacZ, rasN19, and rhoAN17 were previously described (14–16). The
cDNA of the constitutively active Gai2QL mutant or of bcl-2 was in-
serted into the pcDNA expression vector (Invitrogen) or the Pac expres-
sion vector to yield an expression plasmid for Gai2QL or bcl-2, respec-
tively (17).
Analysis of Apoptotic Phenotypes—Cells were grown on glass cover-
slips and fixed at 48 h after transfection by incubation in methanol/
acetone for 2 min. Immunostaining of b-galactosidase and staining of
the genomic DNA were performed as described (18). Cells expressing
LacZ were counted using a Zeiss Axiovert 35 fluorescence microscope.
200–1200 cells were counted in each experiment. Preparation of COS-7
cells for flow cytometric analysis were done with the Apo-Direct kit
following the manufacturer’s instructions. The total cell population
(transfected and non-transfected cells) was used for the flow cytometric
analysis. The total amount of DNA used in the assays was kept con-
stant. Terminal deoxynucleotidyltransferase-mediated dUTP nick end
labeling (TUNEL) assay was performed as described in the in situ
detection kit manufacturers’ instructions. Coverslips were mounted on
glass slides using Vectashield mounting medium containing 49,6-dia-
midino-2-phenylindole to visualize the nuclear morphology of the cells.
RESULTS
Expression of Constitutively Active Ga13 and Gaq but not
Gai2 Triggers Apoptosis—Mutations in the catalytic domain of
Ga-subunits have been described which inhibit their intrinsic
GTPase activity and therefore convert these proteins into con-
stitutively active a-subunits (19). To investigate the phenotype
of cells transfected with constitutively active Ga-subunits, the
nuclear morphology of the transfected cells was analyzed. The
characteristic nuclear phenotype exhibited by apoptotic cells
(nuclear fragmentation and condensation of genomic DNA) was
used to distinguish between normal and apoptotic cells (Fig. 1).
To eliminate the background of non-transfected cells, cells were
cotransfected with expression plasmids for the constitutively
active Ga-subunit and LacZ. Only cells expressing LacZ were
counted during the experiment. Expression of the various pro-
teins was verified by Western blot analysis (data not shown). In
general, a large fraction of singly transfected cells are also
cotransfected with a second plasmid. Thus, there is a high
probability that LacZ positive cells are also expressing the
cotransfected G-protein expression plasmid.
Expression of constitutively active Gai2QL in COS-7 cells
does not increase the number of apoptotic cells over that ob-
served in control experiments where LacZ alone was expressed.
In contrast, expression of constitutively active GaqRC and
Ga13QL increased the appearance of the apoptotic phenotype
dramatically. An approximate three-fold rise in the percentage
of apoptotic cells was observed. Both GaqRC and Ga13QL
expression triggered programmed cell death in nearly 30% of
the transfected cells (Fig. 2A). Varying the amount of expres-
sion plasmid (0.05–1 mg) revealed no differences in the occur-
rence of the apoptotic phenotype in our assays (data not
shown). Thus, differences in the ability to trigger apoptosis
does not appear to be dependent on expression levels of the
FIG. 1. Nuclear fragmentation
caused by expression of constitu-
tively active Ga-subunits. Approxi-
mately 1 3 105 CHO and COS-7 cells were
transiently cotransfected with 0.5 mg of
pCisLacZ and pCisGa13 or pCis. After
48 h, cells were fixed and stained as de-
scribed under “Experimental Proce-
dures.” A representative field is shown
through the respective filters. A, Hoechst
staining of cell nuclei; B, Texas Red stain-
ing of LacZ (Ga13QL/LacZ) expressing
cells. Cells expressing Ga13QL display a
fragmented nucleus and condensed DNA,
whereas only LacZ transfected cells do
not. Expression of GaqRC in CHO cells or
Ga13QL and GaqRC expression in COS-7
cells causes a similar phenotype (data not
shown). Transfections were performed
with LipofectAMINE.
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different Ga-subunits.
To rule out the effect of cell line specific mutations that could
lead to differences in cell survival, CHO cells were also trans-
fected with expression plasmids for GaqRC, Ga13QL, and
Gai2QL. Again in the CHO cell system the expression of
GaqRC and Ga13QL led to significant apoptotic cell death,
whereas Gai2QL expression did not (Fig. 2B). Thus, the results
with the CHO cells correspond to the data obtained using the
COS-7 cells and, together they suggest that the ability of Ga13
and Gaq to induce programmed cell death in tissue culture is
cell type independent.
A second assay system was employed to further confirm the
correlation between the expression of GaqRC and Ga13QL and
apoptosis. The Apo-Direct assay (Phoenix Flow Systems) was
used to detect increased activity of an endonuclease, an addi-
tional characteristic of apoptotic cell death, in the transfected
cells. In this assay fluorescently labeled nucleotides are incor-
porated into the ends of the fragmented, genomic DNA via
terminal transferase. Therefore an increase in fluorescence
intensity indicates an increase in the amount of apoptotic cells.
COS-7 cells expressing GaqRC and Ga13QL exhibit an in-
crease in incorporation of fluorescently labeled nucleotides
(Fig. 3). This is consistent with the observed morphological
nuclear changes in the transfected cells and confirms the no-
tion that Ga13QL and GaqRC expression causes apoptosis.
Induction of Apoptosis by GaqRC and Ga13QL Occurs in
High Serum—Most proteins involved in both apoptotic and
non-apoptotic signaling trigger an apoptotic phenotype only in
low serum. This is thought to be caused by the imbalance of
proliferative signals given by overexpression of these proteins
and by cell cycle arrest imposed by serum starvation (20).
Whereas activation of Gaq causes a strong proliferative re-
sponse, Ga13 has only a modest effect on cell proliferation (21).
LipofectAMINE transfection requires incubation of the trans-
fection mixture for 5 h in serum-free medium. Although 5 h in
serum-free medium is not sufficient for the cells to cease pro-
gression through the cell cycle, another transfection protocol
FIG. 2. GaqRC and Ga13QL expression triggers programmed
cell death in transiently transfected COS-7 and CHO cells. Cells
were cotransfected with GaqRC, Ga13QL, or Gai2QL and LacZ. 48 h
after LipofectAMINE transfection, cells were stained as described un-
der “Experimental Procedures.” Cells expressing LacZ and cells ex-
pressing both LacZ and showing an apoptotic nuclear phenotype were
counted. The percentage of transfected cells showing fragmented nuclei
are presented in these figures. Vertical bars represent 6 S.D. A, trans-
fection of COS-7 cells; B, transfection of CHO cells.
FIG. 3. Increased fragmentation of genomic DNA due to
GaqRC and Ga13QL expression. COS-7 were transfected with
GaqRC, Ga13QL, or LacZ. 48 h after transfection with LipofectAMINE,
cells were fixed and treated according to the Apo-Direct staining pro-
tocol. Treated cells were analyzed in the Coulter Elite flow cytometer at
488 nm excitation. Data were plotted as a histogram. Relative fluores-
cence intensities are marked on the x axis.
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was used to keep the cells in high serum throughout the ex-
periment. Therefore, to determine if the expression of Ga13QL
and GaqRC also cause an imbalance in cell cycle signaling,
transfections were performed with Ca3(PO4)2 in COS-7 cells in
high serum. Even at continuous culture in 10% FBS, expres-
sion of Ga13QL and GaqRC increased the appearance of the
apoptotic nuclear phenotype 2–3- fold compared with the
amounts observed in control experiments (Fig. 4). These data
confirm that constitutive activation of Ga13 and Gaq can acti-
vate pathways directly targeting the cell death machinery.
Signaling Pathways Activated by Gaq and Ga13 Leading to
Apoptosis Are Different but Converge at a Step Controlled by
bcl-2—To investigate the signaling mechanism connecting the
expression of Ga13QL and GaqRC to apoptosis, the effects of
inhibitors of different pathways on apoptotic cell morphology
were examined in COS-7 cells. Although some of the cellular
responses caused by activation of Ga13 and Gaq are similar,
Gaq and Ga13 activate different pathways. Whereas the target
of Gaq signaling is the family of phospholipase C-b enzymes,
Ga13 does not activate this class of enzymes (21–24). In con-
trast, several groups have established that a major target of
Ga13 signaling is the small G-protein Rho (25). Therefore, to
test the involvement of the Rho and the phospholipase C-b
pathways in the induction of apoptosis by GaqRC and Ga13QL,
two different approaches were employed. First cells were co-
transfected with expression plasmids for Ga13QL or GaqRC
and a dominant interfering RhoA mutant (RhoAN19) (Fig. 5A).
Coexpression of RhoAN19 with Ga13QL compared with
Ga13QL expression yielded a significant reduction in the
amount of transfected cells displaying an apoptotic nuclear
phenotype. This reduction was not observed when GaqRC and
RhoAN19 were coexpressed (Fig. 5A).
To rule out a general effect of the expression of dominant
negative small G-proteins, the effect of coexpression of a dom-
inant negative Ras mutant (RasN17) in this assay system was
investigated (19). Neither GaqRC- nor Ga13QL-induced apo-
ptosis was reduced by coexpression of RasN17 demonstrating
that the effect of RhoAN19 on Ga13QL-triggered apoptosis was
specific for Rho.
In the second approach toward analyzing these pathways,
protein kinase C inhibitors were added to cells expressing
constitutively active GaqRC and Ga13QL mutants. Calphostin
C and Ro31–8220 were shown to inhibit all isoforms of PKC at
IC50 of 50 or 10 nM, respectively. Thus, 50–100-fold higher
concentrations of the respective inhibitors were used in these
assays. Inhibition of other kinases by these inhibitors is effec-
tive only at approximately 500–1000-fold higher concentra-
tions (26, 27). Whereas both Calphostin C and Ro31–8220
diminished the amount of apoptotic cells caused by GaqRC
expression 2–3-fold, Ga13QL-induced programmed cell death
was not significantly altered by the addition of the PKC inhib-
itors (Fig. 5B). This indicates that the PKC inhibitors specifi-
cally interfere with Gaq signaling which leads to apoptosis.
Although Ga13 and Gaq obviously activate different signal-
ing mechanisms, these pathways may converge to initiate the
apoptotic cellular response. Signal transduction pathways trig-
gering the activation of the cell death machinery share common
steps, which in many cases are inhibited by expression of bcl-2
(28, 29). Expression of bcl-2 was shown to inhibit apoptosis in
several cell systems by sequestering molecules of the apoptotic
pathway. To test the effect of bcl-2 on Gaq and Ga13 activated
pathways, COS-7 cells were cotransfected with expression plas-
mids for Ga13QL or GaqRC and bcl-2. Both Ga13QL- and
GaqRC-induced apoptosis were greatly reduced by overex-
pressed bcl-2. The observed 3-fold reduction again confirms the
connection of pathways activated by Ga13 and Gaq to the cell
death machinery (Fig. 6). This also reveals that both pathways
must converge upstream of a point controlled by bcl-2 (Fig. 7).
Activation of the interleukin-1b-converting enzyme-like fam-
ily of cysteine proteases is thought to play a central role in the
programmed cell death pathway (for review see Ref. 5). Prote-
olysis of their many target substrates may be responsible for
the eventual demise of the cell. The interleukin-1b-converting
enzyme-like family of proteases or caspases can be inhibited by
specific peptide inhibitors (30). To determine if activation of
caspases is involved in the observed increase in cell death
induced by Ga13QL and GaqRC, COS-7 cells were cotrans-
fected with LacZ and Ga13QL or GaqRC in the presence of 50
mM of z-VAD.fmk, an irreversible inhibitor of the caspase family
of cysteine proteases. The presence of the peptide inhibitor
prevented the induction of cell death by both Ga13QL and
GaqRC when measured using the TUNEL assay, supporting
the notion that activation of a caspase(s) is involved in
Ga13QL- and GaqRC-induced apoptosis (Table I). Although,
the peptide inhibitor prevented DNA fragmentation, nuclear
integrity still seemed to be affected. Many cells appeared to
display some of the morphological characteristics of apoptosis,
nuclear fragmentation and DNA condensation. These results
are similar to findings previously reported demonstrating that
in BAX-induced programmed cell death inhibition of interleu-
kin-1b-converting enzyme-like proteases with z-VAD.fmk pre-
vented DNA fragmentation but not many of the other morpho-
logical changes associated with apoptosis (31).
DISCUSSION
Collectively, our results suggest that expression of constitu-
tively active Ga13QL or GaqRC mutants trigger apoptosis in
higher eukaryotic cell lines. Different cell lines contain differ-
ent mutations that interfere with the cell death machinery and
render these lines immortal. Ga13QL and GaqRC expression
caused programmed cell death in two different cell lines, thus
affecting a common pathway leading to apoptosis. In addition,
the observed increase in apoptotic cell number correlates with
data obtained with the expression of other proteins or with
extracellular stimuli causing apoptosis, e.g. with expression of
FIG. 4. Expression of GaqRC and Ga13QL triggers apoptosis
also via Ca3(PO4)2 transfection in high serum. COS-7 cells were
cotransfected with pCisLacZ and the expression plasmid for the consti-
tutively active Ga-subunits or an empty expression vector (total 1.5 mg
DNA, 1 3 105 cells). Transfection was performed with Ca3(PO4)2 and
continuous culture in DMEM with 10% FBS as noted under “Experi-
mental Procedures.” 48 h after transfection, transfected cells were
counted, and the percentage of cells displaying an apoptotic nuclear
phenotype was determined.
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MEKK1 in PC12 cells or tumor necrosis factor-a stimulus in
U937 cells (18, 32). The ability of GaqRC and Ga13QL to
activate the cell death machinery also in high serum distin-
guish our data from other studies where apoptosis was only
achieved by simultaneous expression of the respective protein
and incubation in low serum. Therefore, Ga13QL and GaqRC
seem to activate signaling pathways directly linked to the cell
death machinery.
Activation of Gaq can be correlated with an increase in PKC
activity and elevation of internal Ca21 concentration as a result
of phospholipase C-b activation. The role of PKC activation in
apoptosis is not completely clear. In some cell systems PKC
activation inhibits apoptosis, whereas in others PKC activation
can be correlated with the onset of apoptosis (33–35). In our
assay system, the PKC inhibitors totally abolished the apopto-
sis-inducing ability of Gaq. This reveals that PKC signaling is
an essential step in Gaq triggered apoptosis. Elevation of in-
ternal Ca21 levels is often observed in cells dying from apo-
ptosis (36). Therefore, to determine if GaqRC induced an in-
crease in cytoplasmic Ca21 levels that may be associated with
apoptosis, COS-7 cells expressing GaqRC were incubated with
the Ca21 chelator EGTA/AM. Incubation with 10 mM of this
Ca21 chelator provokes only a slight decrease in the number of
apoptotic cells, presumably due to the low concentration of
EGTA/AM used (data not shown). Higher concentrations of the
Ca21 chelator could not be used because of its cytotoxic action
at higher doses during prolonged incubation (37). Interestingly,
a neural disorder, amyotrophic lateral sclerosis, causing neural
cell death presumably by apoptosis is accompanied by an ele-
vation in PKC activity and cytoplasmic Ca21 levels (11). The
cause of this disease is currently unknown.
Sustained activation of Gaq was recently shown to cause
transformation of NIH3T3 cells (38). This study also showed
that a large fraction of the transfected cells died due to expres-
sion of constitutively active Gaq. These data can now be ex-
plained by the correlation between GaqRC and apoptosis that
we found. The transformed phenotype might occur in cells that
accumulate mutations affecting the cell death machinery.
FIG. 5. Investigation of signaling pathways connecting Ga activation with the cell death machinery. COS-7 cells were cotransfected
with 0.5 mg of LacZ, a constitutively active Ga-subunit and a dominant interfering small G-protein or an equal amount of empty vector (A). Cells
expressing LacZ and cells expressing LacZ and showing an apoptotic nuclear phenotype were counted after 48 h. The percentage of transfected cells
undergoing nuclear fragmentation is displayed. COS-7 cells cotransfected with a constitutively active Ga-subunit and LacZ were treated with PKC
inhibitors or with an equal volume of inhibitor solvent as a control (B). Calphostin C (Cal C) and Ro31–8220 were added to a final concentration
of 2 and 1 mM, respectively. Cell morphology was analyzed 48 h after transfection. Transfections were performed with LipofectAMINE.
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Recently it was demonstrated that sustained activation of
Rho triggers programmed cell death in low serum (39). In
contrast, our data show that coexpression of RhoAN19 and
Ga13QL lead to a significant but not total reduction of apo-
ptosis to background levels in the cell population (Fig. 5A).
Therefore, it is likely that RhoAN19 expression levels are too
low to completely prevent Rho-induced apoptosis. On the other
hand, Ga13 might activate an additional pathway that contrib-
utes to the Rho signaling in inducing apoptosis in high serum.
Our data clearly demonstrate that Ga13QL- and GaqRC-
triggered apoptosis can be blocked by overexpression of bcl-2.
Thus, these pathways enter the cell death signaling cascade
upstream of a point controlled by bcl-2. In conclusion, our
results demonstrate the ability of Ga-subunits to induce pro-
grammed cell death through different pathways that, however,
converge before the final execution of cell death.
We also performed experiments where constitutively active
Ga12QL was expressed in COS-7 cells. A significant fraction of
the cells showed the apoptotic phenotype, however, the amount
was well below the fraction of apoptotic cells obtained with
expression of GaqRC and Ga13QL (20% 6 6.08; data not
shown). Recently it was demonstrated that Ga13 and Ga12
recruit different signaling pathways to activate Na1/H1 ex-
changers (40). In addition, null mutation of Ga13 in mice
displays a distinct phenotype, which also argues against redun-
dant functions of Ga13 and Ga12 (41). Therefore, it is likely
that activated Ga13 transmits signals to the cell death machin-
ery through pathways not recruited by Ga12.
Our study clearly demonstrates that sustained activation of
Gaq or Ga13 can trigger apoptosis in different cell systems.
Several human diseases are thought to be caused by a sus-
tained stimulus that cannot be shut down through desensiti-
zation processes. The role of sustained signaling through Gaq
or Ga13 in development and in disease remains to be more
clearly defined.
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